ClinicalTrials.gg
RecruitingNCT07323927Updated Jan 7, 2026

Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease

An Early Phase 1 interventional study of Galcanezumab in Alzheimer Disease, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Xuanwu Hospital, Beijing · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2025, registered Dec 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing — 19 open to participants now, 20 under way, 1 of them phase 3. Alzheimer Disease · Xuanwu Hospital, Beijing.

Planned enrollment
16th of 19
10 · median 40
Started
2025
with 7 others
Phase 1
4 of 26
4 open now
Primary completion
2027-01
later than 7 of 19 live
Registered
21st of 26
by date

Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 8 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 7 of the 19 other live ones, and was the 21st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

19 of the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This single-arm, open-label clinical study systematically evaluates the efficacy and safety of Galcanezumab in patients with mild-to-moderate Alzheimer's disease (AD). Eligible participants who provided written informed consent were screened and enrolled to receive Galcanezumab treatment. The therapeutic regimen involved subcutaneous administration of Galcanezumab with an initial 240 mg loading dose followed by 120 mg maintenance doses every four weeks for six total administrations over a 24-week treatment period. All study procedures were conducted at the Advanced Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University. Comprehensive data collection and clinical assessments were performed at baseline (pre-treatment), week 12 (Visit 3), week 24 (Visit 4), and week 36 (Visit 5, 12 weeks after the final dose) to evaluate treatment outcomes and safety profiles. The study design incorporates standardized clinical trial methodology while maintaining the flexibility required for exploratory therapeutic evaluation.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer disease
  • Galcanezumab
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 50 and 90 years at enrollment, regardless of gender;
  2. Meeting the NIA-AA core clinical criteria for probable Alzheimer's disease;
  3. Clinical Dementia Rating - Global Score (CDR-GS) between ≥1 and ≤2; Clinical Dementia Rating - Memory Box (CDR-Memory box) ≥0.5;
  4. Amyloid PET or cerebrospinal fluid (CSF) biomarkers consistent with AD pathology;
  5. (MMSE) score between ≥12 and ≤26;
  6. Non-illiterate or with at least 4 to 6 years of formal education;
  7. If currently taking psychiatric or cognitive-enhancing medications, the dosage must have been stable for at least 3 months prior to the study and remain unchanged during the study. Unless otherwise specified, all permitted concomitant medications (non-AD related) must have been stable for at least 4 weeks prior to baseline;
  8. Availability of a reliable caregiver or legal guardian able to support the participant throughout the study, defined as spending at least 8 hours per week with the participant;
  9. Willingness to participate in the clinical trial, maintain existing interventions during the study period, and provision of signed .

Exclusion criteria

Exclusion Criteria:

  1. Presence of neuropsychiatric symptoms outside the typical spectrum of Alzheimer's disease;
  2. History of (TIA), stroke, or seizure within the past 12 months;
  3. Known allergy to gantenerumab or its , or severe allergic reactions to monoclonal antibodies;
  4. Cardiovascular or gastrointestinal diseases including severe arrhythmias, uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg), or active peptic ulcer disease, inflammatory bowel disease, or other conditions likely to exacerbate gastrointestinal adverse reactions;
  5. MRI such as cardiac pacemaker/defibrillator or ferromagnetic metal implants;
  6. MRI evidence of other lesions suggesting dementia diagnoses other than AD;
  7. MRI findings of other important pathologies, including but not limited to: single hemorrhagic lesions >10 mm in diameter; evidence of vasogenic edema; brain contusions, softening, aneurysms, vascular malformations, or infectious lesions; strokes involving major vascular territories; severe small vessel or white matter disease; space-occupying lesions; or brain tumors (meningiomas or arachnoid cysts with a maximum diameter \<1 cm may be allowed);
  8. Current participation in another clinical trial targeting AD improvement;
  9. Any unstable or inadequately controlled medical condition, or other situations deemed by investigators to compromise participant safety or study assessments;
  10. Other investigator-determined reasons precluding participant inclusion.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Galcanezumab Treatment Arm (Open-label)

    Subcutaneous Galcanezumab administration with an initial dose of 240 mg (single injection), followed by 120 mg every 4 weeks for a total of 6 doses (24-week treatment duration).

    Drug: Galcanezumab

Interventions

  • Subcutaneous injection; monotherapy (administered at the designated study site: Advanced Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University); initial dose: 240 mg (single administration) followed by 120 mg every 4 weeks for 6 total doses

    Also known as: Emgality

06

What researchers measure

Primary outcomes

  1. CGRP Levels in Cerebrospinal Fluid and Plasma

    Measurement of CGRP levels in cerebrospinal fluid and plasma.

    Time frame: Baseline; 24 weeks.

Secondary outcomes

  1. Change from baseline on the Alzheimer's disease assessment scale-cognitive section(ADAS-Cog)

    Time frame: baseline; 12 weeks; 36 weeks.

  2. Change from baseline on the Alzheimer's disease assessment scale-cognitive section(ADAS-Cog)

    Time frame: baseline; 24 weeks.

  3. Change from baseline on the Mini Mental state Examination (MMSE) score

    Time frame: baseline; 12 weeks; 24 weeks; 36 weeks.

  4. Change from baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)

    Time frame: baseline; 12 weeks; 24 weeks; 36 weeks.

  5. Change from baseline on the Alzheimer's Disease Cooperative study-clinical global impression of change scale(ADCS-CGIC)

    Time frame: baseline; 12 weeks; 24 weeks; 36 weeks.

  6. Change from baseline on the Alzheimer's Disease Cooperative study-Activities of Daily Living Scale(ADCS-ADL)

    Time frame: baseline; 12 weeks; 24 weeks; 36 weeks.

  7. Change from baseline on the Neuropaychiatic Inventory (NPI)

    Time frame: baseline; 12 weeks; 24 weeks; 36 weeks

  8. Change from baseline on the Hamilton depression scale (HAMD)

    Time frame: baseline; 12 weeks; 24 weeks; 36 weeks

  9. Change from baseline in amplitude of Low-Frequency Fluctuations (ALFF) in resting-state functional MRI

    Time frame: baseline; 24 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 73 non-industry phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 17 months is below that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 7, 2026
StartActual
Aug 1, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 31, 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323927
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Aug 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Yi Tang, M.D., Ph.D.
Contact
tangyi@xwhosp.org
00861083199456
Ouyang Chen, Ph.D.
Contact
chenouyang@xwhosp.org
15652888562
Yi Tang
study chair · M.D., Ph.D.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Galcanezumab

Start the discussion